Shai Novik

OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel.

Cazador Acquisition Corp. Ltd. operates as a blank check company. It is incorporated for the purpose of effecting a merger, share capital exchange, asset acquisition, share purchase, reorganization or similar business combination, which the firm refers to as its target business or target businesses. The company was founded on April 20, 2010 and is headquartered in George Town, Cayman Islands.

OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel.

Autovative Products, Inc. operates as a distributor of automotive parts. It develops and produces two products for both automobile and fleet uses, including Portable Tow Truck, a traction aid that helps drivers get their vehicles unstuck from snow, ice, mud and sand; and Overhead Door Saver, a heavy-duty spring device for use in fleets of trucks with overhead doors. The company cushions the shock of constant door openings and reduces overhead door repairs. Autovative Products also engages in the business of designing molds for third parties and owns the rights to the design for an auto traction aid mold. The company was founded on December 8, 2004 and is headquartered in Washington Boro, PA.

OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel.

OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel.

OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel.

OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel.

OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel.

Cazador Acquisition Corp. Ltd. operates as a blank check company. It is incorporated for the purpose of effecting a merger, share capital exchange, asset acquisition, share purchase, reorganization or similar business combination, which the firm refers to as its target business or target businesses. The company was founded on April 20, 2010 and is headquartered in George Town, Cayman Islands.

OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel.

Autovative Products, Inc. operates as a distributor of automotive parts. It develops and produces two products for both automobile and fleet uses, including Portable Tow Truck, a traction aid that helps drivers get their vehicles unstuck from snow, ice, mud and sand; and Overhead Door Saver, a heavy-duty spring device for use in fleets of trucks with overhead doors. The company cushions the shock of constant door openings and reduces overhead door repairs. Autovative Products also engages in the business of designing molds for third parties and owns the rights to the design for an auto traction aid mold. The company was founded on December 8, 2004 and is headquartered in Washington Boro, PA.

THCG, Inc. is currently providing a limited level of investment banking and other financial advisory services through Tower Hill. Prior to November 1, 1999, the Company was a closed-end management investment company with three business focuses: investing in start-up and early stage development companies; operating an investment vehicle that specialized in bridge financing to small and medium-sized companies; and providing accounts receivable-based commercial financing, or factoring and related services. During 2000, the Company provided a combination of venture funding, venture development and venture banking services to its partner companies, comprised of Internet and technology companies in which it acquired direct or indirect equity interests as well as to third parties to which it provided services for fees. THCG is located in New York, NY.

OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel.

Cazador Acquisition Corp. Ltd. operates as a blank check company. It is incorporated for the purpose of effecting a merger, share capital exchange, asset acquisition, share purchase, reorganization or similar business combination, which the firm refers to as its target business or target businesses. The company was founded on April 20, 2010 and is headquartered in George Town, Cayman Islands.

THCG, Inc. is currently providing a limited level of investment banking and other financial advisory services through Tower Hill. Prior to November 1, 1999, the Company was a closed-end management investment company with three business focuses: investing in start-up and early stage development companies; operating an investment vehicle that specialized in bridge financing to small and medium-sized companies; and providing accounts receivable-based commercial financing, or factoring and related services. During 2000, the Company provided a combination of venture funding, venture development and venture banking services to its partner companies, comprised of Internet and technology companies in which it acquired direct or indirect equity interests as well as to third parties to which it provided services for fees. THCG is located in New York, NY.

OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel.

Cazador Acquisition Corp. Ltd. operates as a blank check company. It is incorporated for the purpose of effecting a merger, share capital exchange, asset acquisition, share purchase, reorganization or similar business combination, which the firm refers to as its target business or target businesses. The company was founded on April 20, 2010 and is headquartered in George Town, Cayman Islands.

Cazador Acquisition Corp. Ltd. operates as a blank check company. It is incorporated for the purpose of effecting a merger, share capital exchange, asset acquisition, share purchase, reorganization or similar business combination, which the firm refers to as its target business or target businesses. The company was founded on April 20, 2010 and is headquartered in George Town, Cayman Islands.

THCG, Inc. is currently providing a limited level of investment banking and other financial advisory services through Tower Hill. Prior to November 1, 1999, the Company was a closed-end management investment company with three business focuses: investing in start-up and early stage development companies; operating an investment vehicle that specialized in bridge financing to small and medium-sized companies; and providing accounts receivable-based commercial financing, or factoring and related services. During 2000, the Company provided a combination of venture funding, venture development and venture banking services to its partner companies, comprised of Internet and technology companies in which it acquired direct or indirect equity interests as well as to third parties to which it provided services for fees. THCG is located in New York, NY.

OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel.

THCG, Inc. is currently providing a limited level of investment banking and other financial advisory services through Tower Hill. Prior to November 1, 1999, the Company was a closed-end management investment company with three business focuses: investing in start-up and early stage development companies; operating an investment vehicle that specialized in bridge financing to small and medium-sized companies; and providing accounts receivable-based commercial financing, or factoring and related services. During 2000, the Company provided a combination of venture funding, venture development and venture banking services to its partner companies, comprised of Internet and technology companies in which it acquired direct or indirect equity interests as well as to third parties to which it provided services for fees. THCG is located in New York, NY.

OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel.

OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel.